-
抗凝逆转的“通用解药”：麦科奥特MT1011完成I期临床，剑指临床痛点
Universal Antidote for Anticoagulation Reversal: Micot\x26#39;s MT1011 Completes Phase I Clinical Trial, Targeting Unmet Clinic Needs
넶58 2026-04-29 -
麦科奥特MT2004核心专利获欧洲授权，全球知识产权壁垒再筑新高
Micot Bio Secures European Patent for MT2004，Strengthening Global IP Moat
넶74 2026-04-28 -
-
麦科奥特SPF级动物房顺利通过换证审评，筑牢成药性评价核心基石
Micot Passes Re-Certification Review for SPF Animal Facility, Consolidating the Cornerstone of Its Drugability Evaluation Platform
넶12 2026-04-17 -
喜报！麦科奥特MT1013 Ⅲ期临床研究，顺利完成全部试验参与者入组！
Good News! Micot’s MT1013 Phase Ⅲ Clinical Study Completes Enrollment of All Participants!
넶18 2026-04-10
